PMC:7696151 / 67602-67805
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1969 | 24-32 | Species | denotes | patients | Tax:9606 |
| 1979 | 117-131 | Chemical | denotes | sulphasalazine | MESH:D012460 |
| 1980 | 171-174 | Chemical | denotes | HCQ | MESH:D006886 |
| 1997 | 55-75 | Disease | denotes | rheumatoid arthritis | MESH:D001172 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T126 | 55-75 | Phenotype | denotes | rheumatoid arthritis | http://purl.obolibrary.org/obo/HP_0001370 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T434 | 0-203 | Sentence | denotes | In a prospective trial, patients with the diagnosis of rheumatoid arthritis were scheduled to receive cotreatment of sulphasalazine (1–3 g/day), MXT (7.5–15 mg/week), and HCQ (200 mg/day) for six months. |